T. K. Pal et al. / Bioorg. Med. Chem. Lett. 20 (2010) 3777–3780
3779
A. Supplementary data
MCF 7
AH927
MTT assay
3
2.5
2
Crystallographic data (excluding structure factors) for the struc-
tures in this paper have been deposited with the Cambridge Crys-
tallographic Data Center as supplementary publication numbers
CCDC 682467 and 682468. Copies of the data can be obtained, free
of charge, on application to CCDC, 12 Union Road, Cambridge CB2
1EZ, UK [fax: +44 (0)1223-336033 or e-mail: deposit@ccdc.cam.a-
c.uk]. Experimental details and spectra of all new compounds asso-
ciated with this article can be found, in the online version.
Supplementary data associated with this article can be found, in
1.5
1
0.5
0
0
1
10 20 30 40 50 100
concentration of compound 16 in µM
References and Notes
Figure 1. Cell viability assay for 16 using MCF7 (breast cancer) and AH927 (feline
fibroblast) cell lines.
1. (a) Murray, C. J.; Lopez, A. D. Lancet 1997, 349, 1269; (b) Kosek, M.; Bern, C.;
Guerrant, R. L. Bull. World Health Organ. 2003, 81, 197; (c) Walsh, J. A. Rev. Infect.
Dis. 1986, 8, 228; (d) Huston, C. D.; Haque, R.; Petri, W. A., Jr. Exp. Rev. Mol. Med.
(e) Rossignol, J.-F.; Kabil, S. M.; El-Gohary, Y.; Younis, A. M. Trans. R. Soc. Trop.
Med. Hyg. 2007, 101, 1025.
2. McKerrow, J. H. Exp. Parasitol. 1989, 68, 111.
3. Bruchhaus, I.; Loftus, B. J.; Hall, N.; Tannich, E. Eukaryot. Cell 2003, 2, 501.
4. Scholze, H.; Schulte, W. Biomed. Biochim. Acta 1990, 49, 455.
5. Makioka, A.; Kumagai, M.; Kobayashi, S.; Takeuchi, T. Exp. Parasitol. 2005, 109,
27.
6. (a) Singh, A.; Rosenthal, P. J. J. Biol. Chem. 2004, 279, 35236; (b) Brak, K.; Doyle,
P. S.; McKerrow, J. H.; Ellman, J. A. J. Am. Chem. Soc. 2008, 130, 6404.
7. (a) Grant, W. M.; Kinsey, V. E. J. Biol. Chem. 1946, 165, 485; (b) Kinsey, V. E.;
Grant, W. M. J. Cell. Comp. Physiol. 1947, 29, 289.
8. (a) Sok, D. E.; Choi, D. S.; Kim, Y. B.; Lee, Y. H.; Cha, S. H. Biochem. Biophys. Res.
Commun. 1993, 195, 1224; (b) Ni, L.; Zheng, X. S.; Somers, P. K.; Hoong, L. K.;
Hill, R. R.; Marino, E. M.; Suen, K.-L.; Saxena, U.; Meng, C. Q. Bioorg. Med. Chem.
Lett. 2003, 13, 745; (c) Frankel, B. A.; Bentley, M.; Kruger, R. G.; McCafferty, D. G.
J. Am. Chem. Soc. 2004, 126, 3404; (d) Kerr, I. D.; Lee, J. H.; Farady, C. J.; Marion,
R.; Rickert, M.; Sajid, M.; Pandey, K. C.; Caffrey, C. R.; Legac, J.; Hansell, E.;
McKerrow, J. H.; Craik, C. S.; Rosenthal, P. J.; Brinen, L. S. J. Biol. Chem. 2009, 284,
25697.
9. (a) Fang, S.-H.; Padmavathi, V.; Rao, Y. K.; Venkata, S. D. R. C.; Thriveni, P.;
Geethangili, M.; Padmaja, A.; Tzeng, Y.-M. Int. Immunopharmacol. 2006, 6, 1699;
For reviews on the biological activities of vinyl sulfones, see: (b) Vicik, R.;
Busemann, M.; Baumann, K.; Schirmeister, T. Curr. Top. Med. Chem. 2006, 6,
331; (c) Meadows, D. C.; Gervay-Hague, J. Med. Res. Rev. 2006, 26, 793; (d)
Santos, M. M. M.; Moreira, R. Mini-Rev. Med. Chem. 2007, 7, 1040.
10. For reviews on vinyl sulfone-modified carbohydrates, see: (a) Pathak, T.
Tetrahedron 2008, 64, 3605; (b) Pathak, T.; Bhattacharya, R. Carbohydr. Res.
2008, 343, 1980.
Figure 2. ORTEP diagram of compound 19.
11. Compound 16:
A mixture of mercaptoethanol (2.94 mL, 42.3 mmol) and
TMG (3.90 mL, 33.8 mmol) in DMF (10 mL) was heated at 60 °C for
30 min. Compound 10 (1 g, 4.23 mmol) was added to this mixture and
the mixture was heated at 90–120 °C for 4–5 h with stirring under N2.
After completion (tlc), the reaction mixture was poured into satd.
solution of NaHCO3 (20 mL) and the product was extracted with EtOAc
(3ꢀ 10 mL). The combined organic layers were dried over anhyd.
Na2SO4, filtered and the filtrate was concentrated under reduced
pressure to get
a gummy residue. The residue was purified over silica
gel column (Eluent/EtOAc/pet ether = 1:1) to get the sulfide 13. To
a
well-stirred solution of 13 in dry MeOH (10 mL) was added MMPP
(6.22 g, 12.69 mmol) and the mixture was stirred for 6 h under N2. After
completion of reaction (tlc), MeOH was evaporated to dryness under
reduced pressure and the residue thus obtained was dissolved in satd.
NaHCO3 solution (20 mL). The solution was extracted with EtOAc (3ꢀ
10 mL). The combined organic layers were dried over anhyd. Na2SO4,
filtered and the filtrate was concentrated under reduced pressure to get
a residue. The residue was purified over silica gel column (Eluent/EtOAc/
pet ether = 3:2) to obtain the sulfone 14. To
a well-stirred solution of
14 in pyridine (10 mL) was added solution of MsCl (1.45 mL,
a
12.69 mmol) in pyridine (5 mL) dropwise at 0 °C under N2. After
completion of the addition, the reaction mixture was kept at +4 °C.
After 24 h (tlc), the reaction mixture was poured into ice-cold water
and the solution was extracted with EtOAc (3ꢀ 10 mL). The combined
organic layers were dried over anhyd. Na2SO4, filtered and the filtrate
Figure 3. ORTEP diagram of compound 20.
was concentrated under reduced pressure to get
a residue. The crude
material was stirred at room temperature with Et3N (2 mL) in DCM
(10 mL). After 2 h (tlc), the reaction mixture was concentrated under
Acknowledgments
reduced pressure to get
a residue. The residue was purified over silica
gel column to afford 16 (0.59 g, 45%) in three steps from 10. Eluent/
T.K.P. and T.D. thank the Council of Scientific and Industrial Re-
search (CSIR), New Delhi, India for fellowships. S.K.G. wishes to
thank CSIR for partial financial support. T.P. thanks the Department
of Science and Technology, New Delhi for financial support.
EtOAc/pet ether (1:3). Gummy liquid. ½a D25:5
ꢁ
(–) 42.24 (c 1.50, CHCl3). 1H
NMR (CDCl3): d3.45 (s, 3H), 3.62–3.70 (m, 1H), 3.80–3.86 (m, 1H), 4.59
(s, 2H), 5.05–5.08 (m, 1H), 5.77 (br s, 1H), 6.08 (d, J = 9.6 Hz, 1H), 6.42
(d, J = 16.6 Hz, 1H), 6.61–6.74 (m, 2H), 7.31–7.35 (m, 5H). 13C NMR